Pioglitazone+Citalopram+Chlordiazepoxide

Small molecule

Pioglitazone+Citalopram+Chlordiazepoxide is one of 57 small molecule programs targeting Depressive Disorder. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Depressive DisorderActive, not recruiting

Depressive DisorderPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

93 competitors in Depressive Disorder

#DrugCompanyPhaseTrials

Revia

Bayer Aspirin

Voltaren

Ritalin

Nicorette

Estrace

Crestor

Vyvanse

Spravato

1 10

Effexor

WWyeth-Lederle Vaccines

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Depressive Disorder1 trial

Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder

Completed·TTehran University of Medical Sciences·Phase 2/3·NCT01109030·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pioglitazone+Citalopram+Chlordiazepoxide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pioglitazone+Citalopram+Chlordiazepoxide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pioglitazone+Citalopram+Chlordiazepoxide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tehran University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: TTehran University of Medical Sciences

Pioglitazone+Citalopram+Chlordiazepoxide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Depressive Disorder1 trial

References

Drug Info

Quick Facts

Related News